Experience

Davis Polk advised the joint book-running managers in connection with a $115 million SEC-registered offering of 5,897,435 shares of common stock of Five Prime Therapeutics, Inc. The…

Davis Polk advised the joint book-running managers in connection with a $124.5 million SEC-registered follow-on offering of 3,000,000 shares of common stock of Adamas Pharmaceuticals, Inc…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 4,255,000 shares of common stock of…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 8,152,986 shares of common stock of…

Davis Polk advised the joint book-running managers and representatives of the underwriters in the $800 million public offering by BeiGene, Ltd. of American depositary shares. The ADSs are…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S reopening by Hologic, Inc. of $600 million aggregate principal amount of its 4…

Davis Polk advised the underwriters in connection with an initial public offering of 15,972,221 shares of common stock of Denali Therapeutics Inc., including shares sold pursuant to the…

Davis Polk advised the joint book-running managers in connection with a $190 million SEC-registered common stock offering of 6,139,515 shares of common stock of Revance Therapeutics,…

Davis Polk advised the sole book-running manager in connection with the $50 million follow-on offering of 1,970,000 shares of common stock of Editas Medicine, Inc. The common…

Davis Polk is advising Aetna on its approximately $77 billion acquisition by CVS Health. The transaction, which is expected to close in the second half of 2018, is subject to approval by…